Prenetics Group (PRE)
NASDAQ:PRE
Top Page
Prenetics Group
(NASDAQ:PRE)
Select Model
Select Model
Rating:61Neutral
Price Target:
$22.00
▲(10.22% Upside)
Action:ReiteratedDate:03/13/26
The score is driven by strong technical uptrend signals and a bullish earnings-call outlook with robust growth/margin targets and solid liquidity. These positives are tempered by weak underlying financial performance—continued losses and cash burn—and a valuation profile that offers limited support due to negative earnings.
Positive Factors
Rapid IM8 Revenue Scale
IM8’s rapid scale to a $120M ARR within ~12 months indicates strong product-market fit and recurring demand. Durable subscription dynamics and international distribution across ~30 markets increase predictability of revenue and support multi-period growth as the company scales operations and marketing.
Negative Factors
Negative Cash Flow
Multi-year negative operating and free cash flow indicate the company is burning cash to scale. Even with strong liquidity, persistent negative cash generation increases reliance on asset sales or capital markets, raising execution and dilution risk if revenue growth or margin improvements slow.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid IM8 Revenue Scale
IM8’s rapid scale to a $120M ARR within ~12 months indicates strong product-market fit and recurring demand. Durable subscription dynamics and international distribution across ~30 markets increase predictability of revenue and support multi-period growth as the company scales operations and marketing.
Read all positive factors
Prenetics Group (PRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$335.90M
Dividend YieldN/A
Average Volume (3M)244.90K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth159.45%
EPS Growth8.59%
CountryUS
Employees285
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.77
Shares Outstanding15,247,465
10 Day Avg. Volume164,816
30 Day Avg. Volume244,898
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.27
Price to Sales (P/S)2.40
P/FCF Ratio-10.05
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit4.97
Enterprise Value/Ebitda-6.11
Forecast
1Y Price Target
$32.50Price Target Upside62.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$189.92M
Prenetics Group Business Overview & Revenue Model
Company Description
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system th...
How the Company Makes Money
Prenetics makes money primarily by selling testing products and laboratory services. Key revenue streams have included: (1) Consumer and patient testing: revenue from at-home or consumer-initiated genetic tests and health screening tests, where cu...
Prenetics Group Earnings Call Summary
Earnings Call Date:Feb 18, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jun 08, 2026
Earnings Call Sentiment Positive
The call presents a strongly positive operational and financial transformation driven by IM8: exceptional top-line growth (FY revenue +480% YoY), rapid product-market fit (IM8 $120M run rate), improving gross margins (~59% consolidated; IM8 63%), healthy unit economics (LTV:CAC ~3x; payback ~3.4 months) and a fortified balance sheet (~$171M liquidity, 0 debt). Near-term risks include ongoing adjusted EBITDA losses with FY2026 guidance widening to $16M–$20M as the company invests to scale, revenue concentration in IM8 (~65% of FY2025 revenue), historical CAC inefficiency in 2025, reliance on intensive marketing spend, and residual crypto exposure. Overall, the positive growth trajectory, margin profile, and strong liquidity substantially outweigh the near-term profitability and concentration risks.Positive Updates
Record Full-Year Revenue and Exceptional Growth
Total revenue for FY2025 was $92.4 million, a 480% year-over-year increase driven primarily by IM8.
Negative Updates
Continued Adjusted EBITDA Loss and Near-Term Widening
While 2025 adjusted EBITDA loss improved to $13 million, management expects FY2026 adjusted EBITDA loss of approximately $16 million to $20 million as the company continues to invest in growth, delaying profitability until Q4 2027.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Full-Year Revenue and Exceptional Growth
Total revenue for FY2025 was $92.4 million, a 480% year-over-year increase driven primarily by IM8.
Read all positive updates
Company Guidance
Prenetics reiterated 2026 guidance calling for IM8 revenue of approximately $180–$200 million (nearly 300% YoY growth), a target consolidated gross margin of ~60%, and a full‑year adjusted EBITDA loss of about $16–$20 million, with a clear path to adjusted EBITDA profitability by Q4 2027. Management anchored that outlook to a strong 2025 base—$92.4 million total revenue (up ~480% YoY), IM8 $60.1 million for the year and $27.4 million in Q4 (company Q4 revenue $36.6 million), 2025 gross profit $48.9 million (Q4 gross profit $21.7 million) with Q4 consolidated gross margin ~59% and IM8 at 63%—and operational metrics including an IM8 first‑year annualized run‑rate of $120 million, blended LTV:CAC of ~3x, a 3.4‑month payback period, blended AOV rising from $110 in 2025 to ~ $233 in early 2026, an 80% new‑customer subscription rate, and a fortified balance sheet of ~$171.1 million in adjusted liquid assets with zero debt.Prenetics Group Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 92.39M | 30.62M | 21.74M | 13.16M | 12.53M |
| Gross Profit | 48.94M | 15.40M | 8.83M | 3.62M | 3.60M |
| EBITDA | -33.60M | -51.57M | -47.90M | -218.04M | -209.16M |
| Net Income | -58.32M | -46.30M | -62.72M | -190.45M | -174.01M |
Balance Sheet | |||||
| Total Assets | 203.52M | 213.57M | 254.17M | 312.13M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 61.49M | 62.81M | 72.74M | 184.12M | 45.19M |
| Total Debt | 2.20M | 5.77M | 2.37M | 6.65M | 491.67M |
| Total Liabilities | 29.01M | 42.23M | 44.01M | 68.67M | 549.40M |
| Stockholders Equity | 174.60M | 170.39M | 206.36M | 237.06M | -400.81M |
Cash Flow | |||||
| Free Cash Flow | -22.02M | -29.94M | -14.68M | 8.17M | 2.00M |
| Operating Cash Flow | -21.81M | -28.87M | -13.76M | 14.51M | 13.42M |
| Investing Cash Flow | -35.79M | 38.54M | -82.95M | -46.14M | -22.02M |
| Financing Cash Flow | 37.54M | -3.34M | -4.70M | 143.32M | 29.32M |
Prenetics Group Technical Analysis
Positive
19.96
Price Trends
19.38
Positive
17.23
Positive
13.78
Positive
Market Momentum
0.31
Positive
50.91
Neutral
19.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Positive. The current price of 19.96 is below the 20-day moving average (MA) of 20.58, above the 50-day MA of 19.38, and above the 200-day MA of 13.78, indicating a neutral trend. The MACD of 0.31 indicates Positive momentum. The RSI at 50.91 is Neutral, neither overbought nor oversold. The STOCH value of 19.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRE.
Prenetics Group Risk Analysis
Prenetics Group disclosed 58 risk factors in its most recent earnings report. Prenetics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our securities may be delisted from NASDAQ as a result of our failure of meeting the NASDAQ continued listing requirements. Q4, 2023
2.
Our securities may be prohibited from being traded in the United States under the Holding Foreign Companies Accountable Act in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The Holding Foreign Companies Accountable Act, as amended by the Consolidated Appropriations Act, 2023, decreased the number of "non-inspection years" from three years to two years, and thus, reduced the time before our securities may be prohibited from trading or delisted. The delisting of our securities, or the threat of them being delisted, may materially and adversely affect the value of your investment. Q4, 2023
3.
You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations, and a majority of our directors and executive officers reside, outside of the United States. Q4, 2023
Prenetics Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $335.90M | -3.79 | -36.02% | ― | 159.45% | 8.59% | |
57 Neutral | $175.50M | -2.82 | -9.93% | ― | 5.44% | 72.17% | |
52 Neutral | $458.26M | -4.66 | -52.04% | ― | -41.87% | -165.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $121.93M | -2.33 | -138.87% | ― | 78.62% | 32.39% | |
44 Neutral | $74.08M | -6.57 | -126.62% | ― | 14.08% | 1.34% | |
43 Neutral | $105.30M | -5.33 | 516.59% | ― | 21.68% | 58.30% |
* Healthcare Sector Average
PRE
Prenetics Group
19.96
16.14
422.51%
ACRS
Aclaris Therapeutics
3.80
2.47
185.71%
MDXH
MDxHealth
2.05
0.61
42.36%
STIM
Neuronetics
1.76
-1.79
-50.42%
XGN
Exagen
3.08
-1.00
-24.51%
BNR
Burning Rock Biotech
16.30
12.67
349.04%
Prenetics Group Corporate Events
Prenetics Launches $40 Million Buyback as IM8 Growth, Liquidity Bolster Valuation Case
Mar 6, 2026
On March 6, 2026, Prenetics announced that its board authorized a 12‑month share repurchase program of up to $40 million in Class A ordinary shares, underscoring management’s belief that the stock is undervalued. The move follows about...
Prenetics Executives Boost Personal Share Purchases to $2.75 Million After Earnings
Mar 3, 2026
Prenetics Global Limited, a Nasdaq-listed consumer health sciences company and parent of the fast-growing IM8 premium nutrition brand, is expanding its position in the global wellness market with science-backed supplements sold in over 30 countrie...
Prenetics Posts Record 2025 Results as IM8 Hits $120 Million ARR and Drives Strategic Refocus
Feb 18, 2026
Prenetics Global Limited, a consumer health sciences company and parent of the IM8 premium health and longevity brand, reported that 2025 was a transformational year marked by record growth and a strategic refocus on IM8. The company divested non-...
Prenetics Reshapes Board and Strategy to Accelerate Global IM8 Longevity Push
Feb 17, 2026
On February 17, 2026, Prenetics Global Limited announced board changes tied to its strategic pivot toward scaling IM8 as a global health and longevity brand. Director Kong Yiu (Andy) Cheung resigned effective February 16, 2026, a move the company ...
Prenetics Sells Insighta Stake to Tencent for $70 Million, Sharpening Focus on IM8
Feb 17, 2026
On February 17, 2026, Prenetics Global Limited announced it had completed the sale of its 35% equity stake in cancer-screening venture Insighta to Tencent for $70 million in cash, marking the final step in a wider strategic overhaul. The deal lift...
Prenetics Sells Europa 3PL Unit to Sharpen Focus on High-Growth IM8 Brand
Jan 6, 2026
On January 1, 2026, Prenetics Global Limited completed the sale of its third-party logistics distribution business operated by subsidiary Europa Sports Partners in an all-stock transaction valued at up to $13 million, as disclosed in a January 6, ...
Prenetics Lifts Warrant Exchange Participation to 86.7%, Sharply Reducing Potential Dilution
Jan 5, 2026
On January 5, 2026, Prenetics Global Limited reported that participation in its voluntary warrant exchange program tied to its October 2025 financing round had reached approximately 86.7%, with exchange agreements now covering about 4.72 million o...
Prenetics Halts Bitcoin Purchases to Channel Capital Into High-Growth IM8 Brand
Dec 30, 2025
On December 30, 2025, Prenetics Global Limited announced a major capital allocation shift, confirming that it stopped its daily Bitcoin purchases on December 4 and will no longer deploy capital into additional cryptocurrency acquisitions. The comp...
Prenetics Launches Major Warrant Exchange to Cut Dilution and Simplify Capital Structure
Dec 23, 2025
On December 23, 2025, Prenetics Global Limited announced that it had entered into warrant exchange agreements with holders representing about 83.4% of its outstanding Class A and Class B warrants issued in an October 2025 financing. Under the volu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.